

ADAPT CONSORT Flow Diagram

Enrollment

Diagnosis of histologically confirmed unilateral primary invasive carcinoma of the breast

Diagnostic core biopsy and local pathology assessment (hormone receptor & HER2 status)

Excluded

- Not meeting eligibility criteria
- Declined to participate
- Other reasons

Allocation

ADAPT HR+/HER2-

ADAPT HER2+/HR+

ADAPT HER2+/HR-

ADAPT Triple Negative

3 weeks induction treatment

Central pathology review of diagnostic core biopsy (hormone receptor & HER2 status)

Efficacy assessment

Repeat core biopsy*/surgery**

Randomization

Excluded

- Screening failure

Risk assessment

Randomization

N0-1

N2-3

3 weeks induction treatment

Arm A

Arm B

Arm C

Arm A

Arm B

Arm A

Arm B

RS \leq 11 or RS12-25 and response

RS \geq 26 or RS12-25 and low response

Repeat core biopsy

Arm A

Arm B

Arm C

Arm A

Arm B

Arm A

Arm B

Endocrine therapy (ET)

Randomization

Arm A

Arm B

Pathologic complete response (pCR) assessment

End of treatment

Surgery*

Surgery

Follow-Up

Completed follow-up protocol
Discontinued treatment
Lost to follow-up

ADAPT HR+/HER2-

ET

Arm A

Arm B

ADAPT HER2+/HR+

Arm A

Arm B

Arm C

ADAPT HER2+/HR-

Arm A

Arm B

ADAPT Triple Negative

Arm A

Arm B

Analysis

Analysed
Excluded from analysis

ADAPT HR+/HER2-

ET

Arm A

Arm B

ADAPT HER2+/HR+

Arm A

Arm B

Arm C

ADAPT HER2+/HR-

Arm A

Arm B

ADAPT Triple Negative

Arm A

Arm B